Search company, investor...
CardioLabs company logo


Founded Year



Acquired | Acquired

About CardioLabs

CardioLabs provides cardiac event monitoring and mobile cardiac telemetry services. On June 2, 2021, CardioLabs was acquired by AliveCor. The terms of the transaction were not disclosed.

Headquarters Location

357 Riverside Dr, Suite 1000

Franklin, Tennessee, 37067,

United States


Missing: CardioLabs's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CardioLabs's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CardioLabs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CardioLabs is included in 2 Expert Collections, including Telehealth.



2,856 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.


Digital Health

13,069 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest CardioLabs News

AliveCor Acquires CardioLabs, Aims to Launch Advanced Ambulatory Monitoring Services

Jun 7, 2021

AliveCor , Mountain View, Calif., known for its FDA-cleared personal electrocardiogram (ECG) technology and services, has acquired the independent diagnostic testing facility (IDTF) CardioLabs, a leading monitoring and cardiac diagnostic service provider. The acquisition is a cornerstone of AliveCor’s mission to extend its comprehensive cardiological services to patients who are prescribed monitoring devices by their healthcare providers. “The acquisition of CardioLabs sets AliveCor on a course to becoming the premier provider of end-to-end cardiac diagnostic support,” says Priya Abani, CEO, AliveCor. “We are creating new opportunities for healthcare providers and patients through enhanced, reimbursed cardiac monitoring services and access to real-time data that helps inform clinical decision-making.”  With the acquisition, AliveCor now manages CardioLabs’ U.S.-based healthcare provider customers and plans to expand the service to new customers in the coming months. Existing CardioLabs customers will retain access to the full suite of cardiac monitoring services previously available to them including mobile cardiac telemetry, cardiac event monitoring, extended holter and holter monitoring. Longer-term, AliveCor’s KardiaMobile 6L will be made available to CardioLabs customers as the world’s first and only wireless, patchless, six-lead cardiac monitor. Share:

CardioLabs Frequently Asked Questions (FAQ)

  • When was CardioLabs founded?

    CardioLabs was founded in 1995.

  • Where is CardioLabs's headquarters?

    CardioLabs's headquarters is located at 357 Riverside Dr, Suite 1000, Franklin.

  • What is CardioLabs's latest funding round?

    CardioLabs's latest funding round is Acquired.

  • Who are the investors of CardioLabs?

    Investors of CardioLabs include AliveCor.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.